We are enclosing herewith the Press Release on Successful closure of USFDA inspection under 21 CFR 20.64(d)(3).
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care announced that the USFDA has formally closed its inspection of the company's Vapi manufacturing plant under 21 CFR 20.64(d)(3), making the facility fully qualified to export Drug (OTC) products to the US market. The audit process began in September 2024 and concluded in March 2025 after the company renovated and upgraded its facility, which had impacted production over the past six months. The company expects to receive monthly export orders worth ₹2.50–3.00 Crores and annual orders of ₹30–36 Crores from the US, leveraging India's lower 10% tariff versus China's 30%. Veerhealth also guided to a revenue target of ₹100 Crores with 10% PAT margin over the next 24–36 months, supported by full-capacity operations.
This is a significant positive development — the USFDA clearance opens a major export revenue stream and positions the company for strong topline and margin growth. Shareholders can expect revenue acceleration and improved profitability as the US orders ramp up, though execution and full-capacity utilization will be key watchpoints.